Omnicell (NASDAQ:OMCL) Price Target Raised to $34.00 at Bank of America

Omnicell (NASDAQ:OMCL) had its target price hoisted by Bank of America from $30.00 to $34.00 in a research note published on Friday morning,Benzinga reports. They currently have a neutral rating on the stock.

A number of other research analysts also recently commented on OMCL. Wall Street Zen raised Omnicell from a “hold” rating to a “buy” rating in a research note on Tuesday. Wells Fargo & Company raised their target price on shares of Omnicell from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Friday. Benchmark dropped their target price on shares of Omnicell from $62.00 to $40.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Omnicell currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.83.

Omnicell Stock Down 2.1%

Shares of OMCL opened at $28.23 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell has a 12 month low of $22.66 and a 12 month high of $55.75. The firm’s 50 day moving average is $30.94 and its 200-day moving average is $38.81. The stock has a market capitalization of $1.32 billion, a PE ratio of 104.56, a P/E/G ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.10. The firm had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The company’s revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the company earned $0.03 EPS. Equities research analysts forecast that Omnicell will post 1.09 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Smartleaf Asset Management LLC boosted its stake in shares of Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after purchasing an additional 273 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in Omnicell by 6.9% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company’s stock valued at $213,000 after purchasing an additional 307 shares during the last quarter. Van ECK Associates Corp lifted its stake in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after purchasing an additional 315 shares during the last quarter. First Horizon Advisors Inc. boosted its position in Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after buying an additional 355 shares in the last quarter. Finally, Redmond Asset Management LLC grew its stake in shares of Omnicell by 0.3% during the fourth quarter. Redmond Asset Management LLC now owns 121,209 shares of the company’s stock worth $5,396,000 after buying an additional 371 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.